Giulia F. Manfredi
Du Cane Road
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 13, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 28, 2025
Thinking outside the box: a case of unexplained ascites in an adult.
Journal: Internal and emergency medicine
Published: October 06, 2025
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: September 04, 2025
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.
Journal: JHEP reports : innovation in hepatology
Published: July 04, 2025
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
Journal: JHEP reports : innovation in hepatology
Published: May 06, 2025
Impact of Age and Sex on Viral Load in Hepatitis C Virus Infection.
Journal: Viruses
Published: December 05, 2024
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.
Journal: Expert review of gastroenterology & hepatology
Published: October 22, 2024
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.
Journal: The Lancet. Digital health
Published: October 01, 2024
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 12, 2024
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.
Journal: JHEP reports : innovation in hepatology
Published: August 05, 2024
Last Updated: 09/26/2026